Clinical Trial Update: Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Depression [Phase 2]

View source ↗

Summary

Phase 2 study evaluating inhaled esketamine for treatment-resistant depression completed, reporting efficacy, safety, and pharmacokinetics.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Esketamine (esketamine)

Snippet

Sponsor: Celon Pharma SA | Conditions: Major Depressive Disorder | Phase 2 | Status: COMPLETED